The University of Chicago Header Logo

Connection

Mark J. Ratain to Receptor, ErbB-2

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Receptor, ErbB-2.
Mark J. Ratain
Connection Strength
0.078
Receptor, ErbB-2
  1. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
    View in: PubMed
    Score: 0.049
  2. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.